EFFECT OF COMBINATION INTERLEUKIN-1 AND ERYTHROPOIETIN IN AMELIORATING THE HEMATOPOIETIC TOXICITY ASSOCIATED WITH THE USE OF ZIDOVUDINE ADMINISTERED TO NORMAL MICE

Citation
Vs. Gallicchio et al., EFFECT OF COMBINATION INTERLEUKIN-1 AND ERYTHROPOIETIN IN AMELIORATING THE HEMATOPOIETIC TOXICITY ASSOCIATED WITH THE USE OF ZIDOVUDINE ADMINISTERED TO NORMAL MICE, Life sciences, 54(20), 1994, pp. 351-361
Citations number
22
Categorie Soggetti
Biology,"Medicine, Research & Experimental","Pharmacology & Pharmacy
Journal title
ISSN journal
00243205
Volume
54
Issue
20
Year of publication
1994
Pages
351 - 361
Database
ISI
SICI code
0024-3205(1994)54:20<351:EOCIAE>2.0.ZU;2-1
Abstract
Use of the anti-viral drug zidovudine in the treatment of acquired imm unodeficiency syndrome (AIDS) has been associated with the development of hematopoietic toxicity. Several hematopoietic growth factors have been investigated in their ability to modulate such toxicity; however, no single factor has been demonstrated to produce restoration of hema topoiesis following use with zidovudine. We report results describing the effect of combination interleukin-1 (IL-1) and erythropoietin (Epo ) in their ability to modulate the hematopoietic toxicity associated w ith dose-escalation zidovudine administered in normal mice. When admin istered over a six-week period, IL-1 and Epo raised the packed red cel l volume, white blood cell and platelet counts in control mice and mic e receiving dose-escalation zidovudine. These effects were attributed in part to the ability of combination IL-1 and Epo to increase erythro id, myeloid and megakaryocyte progenitor stem cells from bone marrow a nd spleen. These results indicate that use of combined IL-1 and Epo ma y be efficacious in ameliorating the hematopoietic toxicity associated with the use of zidovudine.